Last checked at 21 Oct 2020 09:06
e-therapeutics plc
("e-therapeutics" or the "Company")
Issue of equity
Oxford, UK, 21 October 2020 - e-therapeutics plc (AIM: ETX, "e-therapeutics" or the "Company") announce that on 20 October 2020 an application has been made for the issue of 1,683,333 new ordinary shares of 0.1p each (the "New Ordinary Shares") in order to satisfy the exercise of share options by former Non-Executive Directors. The grant of the share options was announced on 11 February 2020.
An application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 26 October 2020. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.
Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 420,740,129. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
-Ends-
For further information, please contact:
e-therapeutics plc Ali Mortazavi, Executive Chairman and CEO
|
Tel: +44 (0)1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking) | Tel: +44 (0) 207 260 1000 www.numis.com
|
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics and access to big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyse complex genetic datasets, provide a deep understanding of pathological mechanisms and distil actionable insights for the discovery of novel drugs, biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical company.